TaiGen, HEC launch cross-strait newco for HCV combo

TaiGen Biopharmaceuticals Holdings Ltd. (TPex:4157) and the YiChang HEC ChangJiang Pharmaceutical Co. Ltd. (HKSE:1558) subsidiary of HEC Pharm Group (Dongguan, China) launched a newco that intends to develop HCV therapies for Greater China. The partners said the newco will be capitalized with RMB680 million ($100.3 million), and will be based in mainland China.

HEC will invest cash and give the newco Greater China rights to NS5A inhibitor yimitasvir ( DAG-181), and TaiGen will contribute its Greater China rights to HCV protease inhibitor furaprevir ( TG-2349). HEC said the partners will develop them in combination to produce an oral interferon-free HCV treatment for the Chinese market. ...